August 28, 2016 11:47 AM ET

Biotechnology

Company Overview of Renovar, Inc.

Company Overview

Renovar, Inc. engages in the discovery and development of diagnostic tests based on a portfolio of protein biomarkers for kidney disease and transplant monitoring. It provides a portfolio of protein biomarkers that indicate kidney injury using its urinary immunoassay platform; and CFSE Flow Kit that is used for tracking eight generations of cell proliferation in-vivo and in-vitro for mouse and human cells by flow cytometry. The company also offers custom assays and study services to support research activities, including biomarker selection and assay panel development, study design, data analysis, and samples testing. Renovar, Inc. was founded in 1999 and is headquartered in Appleton, Wiscon...

200 East Washington

Appleton, WI 54911

United States

Founded in 1999

Phone:

608-441-2871

Fax:

608-441-2872

Key Executives for Renovar, Inc.

Chief Executive Officer, President and Director
Co-Founder, Chairman of the Board and Chief Scientific Officer
Co-Founder, Vice President and Director
Compensation as of Fiscal Year 2016.

Renovar, Inc. Key Developments

ViveBio Enters Licensing Agreement with Renovar for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring

ViveBio, LLC announced that it has signed a worldwide exclusive licensing agreement with Renovar, Inc. for urine based biomarkers to predict and monitor kidney diseases as well as rejection in transplant recipients. Based upon unique inflammatory protein signatures found in the urine of diseased or injured kidney's, the Renovar technology can be used to assess the health of a patients kidney's, guide therapeutic decision making and help stratify patients by risk for developing acute rejection. Based upon an NIH sponsored, prospective, multicenter study of 280 kidney transplant recipients researchers evaluated the urinary levels of nine messenger RNAs and two proteins which are known to be associated with kidney transplant rejection. They identified Monokine induced by interferon-gamma (MIG) messenger RNA (mRNA) and MIG protein as the clinically significant biomarkers. After further testing, the researchers found that MIG protein was better at ruling out rejection than any of the mRNA's tested. It was also capable of identifying patients likely to have stable long-term kidney function and identify those patients who were unlikely to experience rejection or loss of kidney function over the next 18 months. The investigators noted that urinary MIG protein levels began to increase up to 30 days before clinical signs of kidney injury.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Renovar, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.